Menu

Cellect Biotechnology Ltd. (NASDAQ: APOP)

Complementary equity research reports on Cellect Biotechnology Ltd.

Report Type

Publish Date

link

Q2 2019 Update

3 September 2019

Q1 2019 Update

28 May 2019

2018 Annual Update

8 April 2019

Q3 2018 Update

13 December 2018

Immediate Report

17 October 2018

Q2 2018 Update

20 August 2018

Q1 2018 Update

30 May 2018

Immediate Report

31 January 2018

Immediate Report

10 January 2018

Q3 2017 Update

19 December 2017

Immediate Report

11 November 2017

On September 3 2017 Cellect voluntarily delisted its shares from trading on the TASE, and withdrew from the TASE Analysis program.

Hereafter all equity research is governed by an agreement between Frost & Sullivan and the Company and concerns the securities listed on the NASDAQ.

Report Type

Publish Date

link

Q2 2017 Update

30 August 2017

Q2 2017 Update – Hebrew Appendix

30 August 2017

Q2 2018 Update

20 August 2018

Immediate Report

14 June 2017

Immediate Report – Hebrew Appendix

14 June 2017

Q1 2017 Update

7 June 2017

Q1 2017 Update – Hebrew Appendix

7 June 2017

Initiation of Coverage

27 April 2017

Initiation of Coverage – Hebrew Appendix

27 April 2017

Have Questions?

We have Answers.

Schedule a Complimentary Growth Strategy
Dialogue with an Industry Expert

877.GoFrost

(877.463.7678)

myfrost@frost.com

X